DanDi Bioscience

http://m.biospectator.com/view/news_view.php?varAtcId=11193&ref=https://m.facebook.com/  

This post has been translated from the original article dated 8/31/2020. 

Discovery of 'DD-A257' and application for patent... Confirmation of accumulation of amyloid beta and inhibition of tau phosphorylation through joint research by Professor Minho Moon's team

Dandi Biosciences unveiled 'DD-A257', a new drug candidate for Alzheimer's disease with a new mechanism. It is a new drug candidate that targets bacteria and their by-products based on the theory that bacterial infection affects the onset of Alzheimer's disease by causing neuronal cell death, amyloid beta accumulation, and tau lesions.

Dandibio Science has unveiled "DD-A257," a new drug candidate for Alzheimer's disease, for the first time. It is a new drug candidate that targets bacterial and bacterial-derived byproducts based on the theory that bacterial infection affects the development of Alzheimer's disease by causing neuronal cell death, amyloid beta accumulation, and tau lesions. Dandibio plans to enter clinical trials for the development of treatments for Alzheimer's disease within the next two years after preclinical phase of DD-A257. It will also challenge the development of a diagnostic kit for Alzheimer's disease using newly discovered targets. Park Young-min, CEO of Dandibio, said in a recent meeting with a bio-specifier, "We recently applied for a patent for 'DD A257', a composition for treating multi-electric Alzheimer's dementia." DD-A257 is a new drug candidate that not only exhibits antibacterial effects on certain bacteria involved in the development of Alzheimer's disease, but also inhibits certain products derived from those bacteria. Dandibio has discovered a new biomarker for Alzheimer's disease and a new drug candidate DD-A257 that inhibits it through a four-year joint study with a team of Professor Moon Min-ho of Konyang University, an authority on Alzheimer's disease research in Korea...